Relacorilant benefit seen in taxane-treated ovarian cancer patients

In a phase III trial of 381 people with platinum-resistant ovarian cancer, adding relacorilant to nab-paclitaxel appeared to help across subgroups, including people previously treated with taxanes.} Daughters

“A new subgroup analysis from the phase 3 (large late-stage) ROSELLA trial 1 suggests the answer may be yes.”

Why it matters. A large, final-stage trial in ovarian cancer. This is the kind of result regulators use when deciding whether to approve a treatment.

Nivolumab and ipilimumab linked to long-term survival in stomach cancer trial

In a phase II trial, 32 people with localized stomach or gastroesophageal junction cancer received nivolumab and ipilimumab before surgery, then nivolumab. After a median follow-up of 48.3 months, 84.1% were alive at 4 years; the study found no clear survival improvement over surgery alone.

Why it matters. A mid-stage trial in stomach cancer. Good results at this stage usually still need a larger trial before approval.

Methylphenidate reduced fatigue in people with blood cancers

In a trial of 152 adults with blood cancers and persistent fatigue, methylphenidate improved fatigue scores 5.0 points more than placebo.

Why it matters. A trial in lymphoma, a blood cancer that split people into groups at random, the fairest kind of test.

Chinese doctors described 25 head and neck tumors in 1935

Two physicians in China examined 25 head and neck tumors and described their features. They proposed that the tumors could arise from different stages of development.

Why it matters. Based on data or samples from people with several cancer types. It is not a treatment trial.

Lab study links T-cell state to treatment options for chronic lymphocytic leukemia

In lab tests using blood cells from people with chronic lymphocytic leukemia, researchers found that some T cells struggled to survive the steps needed to make CAR T-cell therapy, but bispecific drugs helped them kill leukemia cells.

“Collectively, our data support a model in which CD8+ T-cell dysfunction in chronic lymphocytic leukaemia reflects accumulation of short-lived, terminally differentiated effector cells rather than canonical exhaustion or irreversible senescence.”

Why it matters. Lab or animal research on chronic lymphocytic leukaemia, a blood cancer. Not yet tested as a treatment in people; many lab results never reach patients.

Review surveys light-chain tests linked to multiple myeloma

The review describes lab methods for detecting and tracking light chains linked to multiple myeloma and amyloidosis, and approaches to tell harmful chains from harmless ones.

Why it matters. Based on data or samples from people with myeloma, a blood cancer. It is not a treatment trial.

Dabrafenib and trametinib restored iodine uptake in some thyroid cancer patients

In a phase II trial, 14 people with radioiodine-resistant thyroid cancer received dabrafenib and trametinib. Nine qualified for radioiodine treatment, and 6 of those 9 regained iodine uptake within 2 weeks.

“Short-course dabrafenib/ trametinib can induce rapid re-differentiation within 2 weeks in a subset of patients with MAPK-driven radioiodine-refractory (no longer responding to treatment) thyroid cancer, supporting individualized BRAF/MEK inhibition duration rather than empiric prolonged treatment.”

Why it matters. A mid-stage trial in thyroid cancer. Good results at this stage usually still need a larger trial before approval.